ArticleEuropean radiology2026
Risk-stratified MRI surveillance for hepatocellular carcinoma in cirrhosis: a prospective cohort study.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCurrent hepatocellular carcinoma (HCC) surveillance relies on semiannual ultrasonography, which has limited sensitivity for early-stage detection. We evaluated the effectiveness of HCC surveillance using gadoxetic acid-enhanced MRI at risk-stratified screening intervals in patients with cirrhosis. MATERIALS AND
methodsWe prospectively enrolled 86 patients with cirrhosis between May 2021 and October 2022. All patients underwent HCC surveillance using gadoxetic acid-enhanced MRI for 3 years at risk-stratified screening intervals ranging from 3 to 36 months, according to the assigned risk category defined by LI-RADS criteria on baseline MRI (low, intermediate, and high risk with LI-RADS LR-3 or LR-4 observations). The primary outcome was surveillance failure, defined as the detection of HCC beyond the Milan criteria.
resultsHCC was diagnosed in 13 patients during the study period. The HCC incidence differed markedly across the MRI risk categories, ranging from 1.9 per 100 person-years in patients with low risk to 73.4 per 100 person-years in those with LR-4 observations. The primary endpoint was met with no surveillance failures (0%; 95% CI: 0-24.7%). Ten cases (76.9%) were identified at a very early stage, and there was one interval cancer (7.7%). Compared to a uniform semiannual surveillance strategy, the risk-stratified approach reduced the number of surveillance examinations by 44.2%.
conclusionHCC surveillance using gadoxetic acid-enhanced MRI at risk-stratified screening intervals resulted in no surveillance failures, a high rate of early-stage tumor detection, and a low incidence of interval cancer. This approach may improve surveillance effectiveness while reducing examination frequency. KEY POINTS: QuestionWhether risk-stratified surveillance intervals for gadoxetic acid-enhanced MRI can maintain early HCC detection while reducing examination burden in cirrhosis remains unknown. FindingsRisk-stratified MRI surveillance detected all 13 incident HCCs within Milan criteria, with zero surveillance failures and a 44.2% reduction in examinations. Clinical relevanceRisk-stratified gadoxetic acid-enhanced MRI surveillance enables personalized screening intervals based on imaging risk categories, maintaining early-stage HCC detection while substantially reducing examination frequency in patients with cirrhosis.
Indexed as
Identifiers
42603173What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.